Irish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Leathanach 1 ó 157 torthaí
Use of truncated cysteine IL28 and IL29 Mutants to treat cancers and autoimmune disorders
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
Cytokines generally stimulate proliferation or differentiation of cells of the hematopoietic lineage or participate in the immune and inflammatory response mechanisms of the body. Examples of cytokines which affect hematopoiesis are erythropoietin (EPO), which stimulates
N-Acetyl-cysteine protects against cardiac damage from subsequently-administered cardio-toxic anthra-cycline in cancer therapy
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
This invention relates to N-acetyl-cysteine having the formula ##STR1## and has as its object the use of this compound to block cardiac damage resulting from the use of anthracyclines, notably adriamycin, in cancer therapy.
The anthracyclines have the general formula ##STR2## and their essential
Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
The present invention relates to novel receptors in the TNF family. A novel receptor has been identified, referred to herein as TRAIN (TNF Receptor in the BRAIN).
The TNF family consists of pairs of ligands and their specific receptors referred to as TNF family ligands
6-substituted amino-4-oxa-1-azabicyclo [3,2,0] heptan-7-one derivatives as cysteine protease inhibitors
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
Cysteine proteases, such as cathepsins B, L, S, and O.sub.2, have been implicated in a number of diseases, including cancer metastasis and invasion (Clin. Exp. Metastasis 1992, 10, 145-155; Cancer Metastasis Rev. 1990, 9, 333-352), arthritis (Int. J. Biochem. 1993, 25,
Anti-transplanted tumor remedy
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
It is a purpose of this invention to create a cytostatic composition for treatment of transplanted tumors in animals by structurally combining antimetabolics (the hydrazide of cystine and of cysteine, respectively) with an alkylating group. In connection with the invention, U.S. Pat. No. 3,897,494,
Compounds for, and methods of, treating cancer and inhibiting invasion and metastases
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION
The invention generally relates to the treatment of cancer, and, more specifically, to compounds that inhibit the ability of cancer cells to invade tissues and cause metastases. Such compounds and methods can be used alone, or together with other anticancer therapies
Inhibition of cancer procoagulant
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION
This invention relates to selective peptidyl inhibitors of cancer procoagulant (CP), a protein elaborated by malignant, but not normal, animal and human cells, and to the use of these selective peptidyl inhibitors in cancer therapy and in CP removal from blood.
BACKGROUND OF
Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-.beta. subfamily and heart disease and cancer diagnoses
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
1. Technical Field
The present invention relates to methods of producing form-specific antibodies for transforming growth factor (TGF)-.beta. subfamily compositions. More specifically, the present invention relates to methods of diagnosing cancer patients by measuring
Method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION
The invention relates generally to the field of medicine, and relates specifically to methods and compositions for inhibiting tumor growth and angiogenesis in a tissue or detecting angiogenesis and tumor growth using compounds based on a specified sequence found within
Anti-mucin antibodies for early detection and treatment of pancreatic cancer
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 28, 2014, is named IMM343US1_SL.txt and is 56,360 bytes in size.
BACKGROUND OF THE
Anti-mucin antibodies for early detection and treatment of pancreatic cancer
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 28, 2014, is named IMM343US1_SL.txt and is 56,360 bytes in size.
BACKGROUND OF THE
Methods of treating cancer with antibodies that target the insulin-like growth factor type I receptor (IGF-1R)
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 14, 2015, is named IMM316US4_SL.txt, and is 31,769 bytes in size.
FIELD OF THE INVENTION
The present
Tethering cysteine residues using cyclic disulfides
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
Many therapeutic molecules form covalent bonds with cysteine residues on their protein targets. The mechanisms of the majority of these molecules were either elucidated long after development or are not fully understood. Recent successful drug discovery efforts, however,
Peptides having a high cysteine content
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
TECHNICAL FIELD
The present invention relates to peptides with a high cysteine content, to nucleic acid sequences encoding said peptides, to vectors comprising said sequences, as well as to pharmaceutical compositions containing said peptides and their use as pharmaceutics.
STATE OF THE ART
A
3,4-Disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,
An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht
- Oibreacha i 55 teanga
- Leigheasanna luibhe le tacaíocht ón eolaíocht
- Aitheantas luibheanna de réir íomhá
- Léarscáil GPS idirghníomhach - clibeáil luibheanna ar an láthair (ag teacht go luath)
- Léigh foilseacháin eolaíochta a bhaineann le do chuardach
- Cuardaigh luibheanna míochaine de réir a n-éifeachtaí
- Eagraigh do chuid spéiseanna agus fanacht suas chun dáta leis an taighde nuachta, trialacha cliniciúla agus paitinní
Clóscríobh symptom nó galar agus léigh faoi luibheanna a d’fhéadfadh cabhrú, luibh a chlóscríobh agus galair agus comharthaí a úsáidtear ina choinne a fheiceáil.
* Tá an fhaisnéis uile bunaithe ar thaighde eolaíoch foilsithe
